Company profile: Bliss Biopharma
1.1 - Company Overview
Company description
- Provider of tumor-targeting and immunotherapy therapeutics, focused on antibody-drug conjugates (ADCs). Offers BB-1701, an anti-HER2 ADC in international multi-center trials for HER2-positive solid tumors, and a diverse ADC pipeline in preclinical and clinical stages. Operates in-house, GMP-compliant antibody and ADC manufacturing to support clinical development and early commercialization.
Products and services
- BB-1701: Clinical-stage anti-HER2 antibody-drug conjugate engineered for treating HER2-positive solid tumors, currently in international multi-center clinical trials across regions for HER2-positive oncology indications
- ADC Product Pipeline: Multi-target portfolio of antibody-drug conjugates addressing different tumor markers, with candidates across various preclinical and clinical stages supporting breadth in targeted oncology development
- GMP Production Capacity: GMP-compliant in-house capability that produces antibodies and ADCs to international standards, supporting clinical development and early commercialization of Bliss Bio’s tumor-targeting therapeutics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Bliss Biopharma
NewBiotics
HQ: United States
Website
- Description: Provider of drug discovery and development focused on molecules that leverage the cycle of drug resistance in cancer and infectious diseases, transforming drug resistances into therapeutic advantages.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NewBiotics company profile →
Lanthiopharma
HQ: The Netherlands
Website
- Description: Provider of drug discovery focused on therapeutic lantipeptide drugs for serious diseases, applying proprietary lanthionine-peptide technology (LanthioPepTM) to generate novel peptide therapeutics with increased resistance to peptidase degradation, high receptor specificity and increased intrinsic activity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lanthiopharma company profile →
Omeros
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies for inflammation and central nervous system disorders, including MASP-2 antibodies (narsoplimab, OMS1029) for lectin pathway diseases such as TA-TMA and lupus nephritis; MASP-3 antibody (OMS906) for PNH; small-molecule PDE7 (OMS527) and PPARγ (OMS405) candidates for addiction; and GPR174 inhibitors for cancer immunotherapy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Omeros company profile →
Centessa Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies and platforms, including SerpinPC, a biologic for hemophilia that inhibits activated protein C to reduce bleeding; an Orexin Receptor 2 agonist program for sleep-wake disorders; the LockBody technology platform designed to enhance immuno-oncology by selectively targeting the tumor microenvironment; and LB101, a conditionally tetravalent PD-L1 X CD47 bispecific monoclonal antibody for advanced solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Centessa Pharmaceuticals company profile →
Adello Biologics
HQ: United States
Website
- Description: Provider of high-quality, affordable biosimilars, leveraging science-led innovation to accelerate development and drive manufacturing efficiency for patients worldwide; headquartered in Piscataway, NJ and led by industry veterans.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adello Biologics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Bliss Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Bliss Biopharma
2.2 - Growth funds investing in similar companies to Bliss Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Bliss Biopharma
4.2 - Public trading comparable groups for Bliss Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →